Posted 25th May 2021 by Nicholas Noakes
Andrew Evans, speaking at the Digital Pathology & AI Congress USA, described new guidelines he helped to draft for validating whole-slide-imaging for diagnostic purposes. First published in 2013 the guidelines were designed to address the fundamental question, “what needs to be done to validate a whole slide imaging for diagnostic use?”. The review producing the new guidelines was published in May 2021.
Posted 18th December 2019 by Joshua Sewell
At the 6th Digital Pathology & AI Congress, Inspirata and Cirdan announced their new technical partnership designed to empower NHS clinical laboratories to accelerate their use of digital pathology.
Posted 28th May 2018 by Jane Williams
As the field of digital pathology continues to evolve, we are discovering new and exciting ways to use and apply the technology. Digital Pathology is entering a new era, revealing an unprecedented breadth and depth of information for cancer research and diagnosis. Whole slide imaging (WSI) will take an important role in the development of future technologies, imaging modalities and systems, and impact clinical workflows, yielding a comprehensive multi-dimensional analysis that would otherwise be impossible!
Posted 22nd September 2017 by Jane Williams
With the recent shift in the industry as the result of this decision, a common question is “What lies in store for digital pathology system manufacturers in the wake of the FDA granting Philips’ de novo classification request for its IntelliSite device?”
Posted 17th May 2017 by Jane Williams
As digital pathology continues to expand the routine use of whole slide imaging (WSI) pathology slide scanners is becoming more common. That said, most of these devices are implemented as stand-alone deployments with no integration with the laboratory’s information system (LIS) technology.